Vatrix Medical, Inc. ("Vatrix") is a medical technology company founded to develop methods to diagnose and treat aneurysmal disease - offer inghealth care providers and patients less invasive, safer and more complete methods to combat the root causes of aneurysmal disease - a fatal disease that causes the walls of blood vessels to expand, weaken and ultimately rupture. headed up by the former CEO of Lumen Biomedical Inc., a maker of a catheter that removes clots from blood vessels. Vatrix was reported as developing a diagnostic kit that can predict the risk of aneurysms in a patient by analyzing the presence of genetic biomarkers in blood and urine such as desmosine, isodesmosine and metalloproteinase. These biomarkers are linked to the degradation of elastin and collagen, proteins that provide strength, support and flexibility to tissue found in blood vessels. Vatrix had been a bioscience finalist in the 2009 Minnesota Cup, the state's annual competition for new companies.
